Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKore Potash PLC Regulatory News (KP2)

Share Price Information for Kore Potash PLC (KP2)

Share Price is delayed by 15 minutes
Get Live Data
2.90    0.00 (0.00%)
Bid:
2.80
Ask:
3.00
Spread: 0.20 (7.143%)
Market Cap: £150.10m
KP2 Live PriceLast checked at - London Stock Exchange

Intraday Kore Potash PLC Share Chart

CDI Monthly Movement

5 Dec 2018 07:00

RNS Number : 4352J
Kore Potash PLC
05 December 2018
Β 

Β 

Β 

5 December 2018

Β 

Kore Potash Plc

("Kore Potash" or the "Company")

CDI Monthly Movement

Β 

Kore Potash plc (ASX: KP2, AIM: KP2, JSE: KP2) (Company) advises the following movements in CDIs over its ordinary shares during November 2018:

Β 

Balance - 31 October 2018

256,808,522

Β 

Net Movement *

(3,655,745)

Β 

Balance - 30 November 2018

253,152,777

Β 

* Increase/(Decrease) in the number of CDIs quoted on ASX as a result of transfers between CDIs quoted on ASX and ordinary shares quoted on AIM and JSE, as required by the ASX to be reported on a monthly basis.

Β 

A copy of the Appendix 3B lodged with the ASX reflecting the movement is attached below.

Β 

Β 

Β 

ENDS

For further information, please visit www.korepotash.com or contact:

Β 

Β 

Kore Potash

Brad Sampson - CEO

Β 

Tel: +27 11 469 9140

Tavistock Communications

Jos Simson

Edward Lee

Β 

Tel: +44 (0) 20 7920 3150

Canaccord Genuity - Nomad and Broker

Martin Davison

James Asensio

Β 

Tel: +44 (0) 20 7523 4600

Β 

Β 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Β 

New issue announcement,

application for quotation of additional securities

and agreement

Β 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Β 

Β 

Name of entity

Kore Potash plc (ASX: KP2)

Β 

ARBN

621 843 614

Β 

We (the entity) give ASX the following information.

Β 

Β 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Β 

1

+Class of +securities issued or to be issued

Β 

CHESS Depositary Interests corresponding to fully paid ordinary shares (CDIs)

Β 

Β 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

Β 

CDIs:

Β 

As at 31 October 2018 256,808,522

Β 

Net transfers* (3,655,745)

Β 

As at 30 November 2018 253,152,777

Β 

* Transfers between CDIs quoted on ASX and ordinary shares quoted on AIM and JSE

Β 

Β 

3

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Increase/(Decrease) in the number of CDIs quoted on ASX as a result of transfers between CDIs quoted on ASX and ordinary shares quoted on AIM and JSE, as required to be reported on a monthly basis.

Β 

Β 

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

Β 

If the additional +securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

Β 

5

Issue price or consideration

Β 

Nil

Β 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Β 

Notification to ASX of the movement of CDIs quoted on ASX and ordinary shares quoted on AIM and JSE.

Β 

Β 

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

Β 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

No

Β 

Β 

6b

The date the security holder resolution under rule 7.1A was passed

N/A

Β 

Β 

6c

Number of +securities issued without security holder approval under rule 7.1

N/A

Β 

Β 

6d

Number of +securities issued with security holder approval under rule 7.1A

N/A

Β 

Β 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Β 

N/A

Β 

Β 

6f

Number of +securities issued under an exception in rule 7.2

N/A

Β 

Β 

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

N/A

Β 

Β 

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

Β 

Β 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

N/A

Β 

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Movements during November 2018

Β 

Β 

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

253,152,777

Chess Depository Interests at a ratio of 1 CDI representing 1 fully paid ordinary share as issued on the ASX (noting that an additional 607,699,916 ordinary shares are at 30 November 2018 quoted on either the AIM market of the London Stock Exchange or the Johannesburg Stock Exchange).

Β 

Β 

Number

+Class

9

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

9

Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Β 

50,000,000

Β 

Β 

1,886,996

Β 

Β 

2,255,000

Β 

Β 

5,881,250

Β 

Β 

660,000

Β 

Β 

1,405,000

Β 

Β 

3,747,005

Β 

Β 

11,734,853

Β 

Β 

13,144,659

Β 

Β 

4,500,000

Β 

Β 

4,000,000

Β 

Β 

17,200,000

Β 

Unlisted Options exercisable at AUD 0.30 each expiring 15 Nov 2019

Β 

Class C Performance Rights each expiring 16 September 2019 (Emp)

Β 

Performance Rights expiring 6 December 2020 (Emp)

Β 

Performance Rights expiring 1 March 2021 (Dir)

Β 

Performance Rights vesting on 31 May 2019 (Dir)

Β 

Performance Shares vesting on 31 May 2019

Β 

Performance Shares under a Short Term Incentive Scheme Plan for 2017

Β 

Performance Shares under the Long Term Incentive Plan

Β 

Equity Warrants exercisable at A$0.30 each expiring 29 March 2021

Β 

Performance Rights expiring 22 May 2022 (Dir)

Β 

Unlisted Options exercisable at Β£0.11 each expiring on 27 June 2020

Β 

Unlisted Options exercisable at Β£0.11 each expiring on 27 June 2028

Β 

Β 

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Β 

Part 2 ‑ Bonus issue or pro rata issue

Β 

11

Is security holder approval required?

N/A

Β 

12

Is the issue renounceable or non-renounceable?

N/A

Β 

13

Ratio in which the +securities will be offered

N/A

Β 

14

+Class of +securities to which the offer relates

N/A

Β 

15

+Record date to determine entitlements

N/A

Β 

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

N/A

Β 

17

Policy for deciding entitlements in relation to fractions

N/A

Β 

18

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

N/A

Β 

19

Closing date for receipt of acceptances or renunciations

N/A

20

Names of any underwriters

N/A

Β 

21

Amount of any underwriting fee or commission

N/A

Β 

22

Names of any brokers to the issue

N/A

Β 

23

Fee or commission payable to the broker to the issue

N/A

Β 

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

N/A

Β 

25

If the issue is contingent on +security holders' approval, the date of the meeting

N/A

Β 

26

Date entitlement and acceptance form and will be sent to persons entitled

N/A

Β 

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

N/A

Β 

28

Date rights trading will begin (if applicable)

N/A

Β 

29

Date rights trading will end (if applicable)

N/A

Β 

30

How do security holders sell their entitlements in full through a broker?

N/A

Β 

31

How do security holders sell part of their entitlements through a broker and accept for the balance?

N/A

Β 

32

How do security holders dispose of their entitlements (except by sale through a broker)?

N/A

Β 

33

+Issue date

N/A

Β 

Β 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

Β 

34

Type of securities

(tick one)

Β 

(a)

+Securities described in Part 1

Β 

(b)

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Β 

Entities that have ticked box 34(a)

Β Additional securities forming a new class of securities

Β 

Β 

Tick to indicate you are providing the information or documents

Β 

35

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

Β 

Β 

36

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

Β 

Β 

37

A copy of any trust deed for the additional +securities

Β 

Entities that have ticked box 34(b)

Β 

38

Number of +securities for which +quotation is sought

Β 

Β 

Β 

Β 

Β 

39

Class of +securities for which quotation is sought

Β 

Β 

Β 

Β 

Β 

40

Do the +securities rank equally in all respects from the +issue with an existing +class of quoted +securities?

Β 

If the additional +securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Β 

Β 

Β 

Β 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

Β 

(if issued upon conversion of another +security, clearly identify that other +security)

Β 

Β 

Β 

Β 

Β 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Quotation agreement

Β 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

Β 

2 We warrant the following to ASX.

Β 

Β· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

Β 

Β· There is no reason why those +securities should not be granted +quotation.

Β 

Β· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

Β 

Β· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

Β 

Β· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

Β 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

Β 

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Β 

Β 

[ signed electronically ]

Sign here: ............................................................Date: 5 December 2018

Joint Company Secretary

Β 

Print name: Henko Vos

Β 

== == == == ==

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
MSCQZLFBVLFLFBZ
Date   Source Headline
5th Mar 20217:00 amRNSChange in JSE Sponsor
3rd Mar 20217:00 amRNSCDI Monthly Movement
18th Feb 20217:00 amRNSUpdated presentation available
12th Feb 20212:06 pmRNSSecond Price Monitoring Extn
12th Feb 20212:00 pmRNSPrice Monitoring Extension
3rd Feb 20217:00 amRNSCDI Monthly Movement
29th Jan 20217:00 amRNSReview of Operations for Q4 2020
15th Jan 20217:00 amRNSIssue of Equity
6th Jan 20217:00 amRNSCDI Monthly Movement
24th Dec 202012:40 pmRNSSecond Price Monitoring Extn
24th Dec 202012:36 pmRNSPrice Monitoring Extension
23rd Dec 20209:06 amRNSSecond Price Monitoring Extn
23rd Dec 20209:00 amRNSPrice Monitoring Extension
22nd Dec 20202:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20202:01 pmRNSPrice Monitoring Extension
22nd Dec 20209:05 amRNSSecond Price Monitoring Extn
22nd Dec 20209:00 amRNSPrice Monitoring Extension
22nd Dec 20208:50 amRNSASX share price query
14th Dec 20207:00 amRNSCorrespondence received from Minister of Mines
3rd Dec 20209:00 amRNSCDI Monthly Movement
2nd Dec 20207:00 amRNSDX Project - DFS Progress Update
24th Nov 20207:00 amRNSChange in Non-Executive Director
12th Nov 20207:00 amRNSCorrection: Updated DX Pre-Feasibility Study
9th Nov 20207:00 amRNSUpdated DX Pre-Feasibility Study
5th Nov 20207:00 amRNSCDI Monthly Movement
27th Oct 20207:43 amRNSReview of Operations for Q3 2020
22nd Oct 20207:00 amRNSDrilling Campaign at DX Project Commences
14th Oct 20207:00 amRNSGovernment approval to drill at DX Project
13th Oct 20207:00 amRNSIssue of Equity
5th Oct 202010:49 amRNSCDI Monthly Movement
30th Sep 20207:00 amRNSWork commences on DFS for the DX Project
22nd Sep 20201:00 pmRNSExpiry of Unlisted Options
21st Sep 202011:30 amRNSPDMR Shareholding
21st Sep 20207:00 amRNSNotice under section 708A(5)(e)
18th Sep 202011:00 amRNSResults of General Meeting and Issue of Shares
14th Sep 20207:00 amRNSRemote access to GM
8th Sep 20207:15 amRNSConfirming participation in Proposed Fundraise
8th Sep 20207:00 amRNSFINANCIAL REPORT FOR HALF YEAR ENDED 30 JUNE 2020
4th Sep 20207:00 amRNSCDI Monthly Movement
2nd Sep 202011:00 amRNSNotice of GM
26th Aug 20209:05 amRNSSecond Price Monitoring Extn
26th Aug 20209:00 amRNSPrice Monitoring Extension
26th Aug 20207:00 amRNSResults of Proposed Fundraise
25th Aug 20204:35 pmRNSProposed Fundraise to raise a minimum of US$7m
5th Aug 20207:00 amRNSCDI Monthly Movement
30th Jul 20207:00 amRNSReview of Operations for Q2 2020
6th Jul 20207:00 amRNSCDI Monthly Movement
26th Jun 202012:30 pmRNSResult of AGM
26th Jun 202010:00 amRNSCEO’s presentation following AGM
25th Jun 20207:00 amRNSIssue of Equity, Performance Rights and Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.